Alkermes (ALKS) Interest Coverage Ratio Growth (3y) (2013 - 2026)
Alkermes (ALKS) Interest Coverage Ratio Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | - |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -3.69% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 75.30% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -72.71% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | -2.64% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 37.62% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Alkermes | 8.07 Bn | 7.41 Bn | 397.90 Mn | -75.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -85.26% |
| Mar 31, 2026 | 41.39% |
| Dec 31, 2025 | -41.99% |
| Sep 30, 2025 | 65.61% |
| Jun 30, 2025 | 88.24% |
| Mar 31, 2025 | 42.82% |
| Dec 31, 2024 | 17.13% |
| Sep 30, 2024 | 80.78% |
| Jun 30, 2024 | 163.88% |
| Mar 31, 2024 | 55.37% |
| Dec 31, 2023 | 63.22% |
| Sep 30, 2023 | 107.71% |
| Jun 30, 2023 | 276.70% |
| Mar 31, 2023 | -24.79% |
| Dec 31, 2022 | 178.15% |
| Sep 30, 2022 | -106.43% |
| Jun 30, 2022 | -95.40% |
| Mar 31, 2022 | -40.65% |
| Dec 31, 2021 | -2,499.74% |
| Sep 30, 2021 | -68.80% |